Table II.
Adjusted comparison of GBM survival analysis among different treatment groups.
| Treatment groups | Survival months estimate, median (range) | Adjusted analysis HR (95% CI) | P-value |
|---|---|---|---|
| Surgery alone (n=1,094) | 2 (0–89) | Reference | |
| All other treatments (n=2,665) | 8 (0–121) | 0.345 (0.320–0.373) | <0.0001 |
| HRT with or without TMZ (n=433) | 4 (0–33) | Reference | |
| SRT with or without TMZ (n=2,204) | 9 (1–121) | 0.531 (0.477–0.591) | <0.0001 |
| HRT without TMZ (n=390) | 4 (0–33) | Reference | |
| HRT with TMZ (n=43) | 3 (1–29) | 0.880 (0.639–1.213) | 0.4344 |
| TMZ alone (n=28) | 6 (1–24) | 0.821 (0.558–1.207) | 0.3150 |
| SRT without TMZ (n=1,818) | 9 (1–121) | Reference | |
| SRT with TMZ (n=386) | 11 (2–56) | 0.863 (0.770–0.967) | 0.0111 |
| Surgery, no RT, no TMZ (n=1,094) | 2 (0–89) | Reference | |
| Surgery, HRT, no TMZ (n=390) | 4 (0–33) | 0.556 (0.495–0.625) | <0.0001 |
| Surgery, SRT, no TMZ (n=1,818) | 9 (1–121) | 0.320 (0.295–0.347) | <0.0001 |
| Surgery, HRT, TMZ (n=43) | 3 (1–29) | 0.484 (0.356–0.660) | <0.0001 |
| Surgery, SRT, TMZ (n=386) | 11 (2–56) | 0.277 (0.244–0.313) | <0.0001 |
| Surgery, no RT, TMZ (n=28) | 6 (1–24) | 0.434 (0.298–0.633) | <0.0001 |
GBM, glioblastoma multiforme; HR, hazard ratio (adjusted for age and Charlson comorbidity index); CI, Wald confidence interval; TMZ, temozolomide; RT, radiation therapy; HRT, hypofractionated RT; SRT, standard RT.